• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

靶向严重急性呼吸综合征冠状病毒2(SARS-CoV-2)两个表位的抗体可中和携带不同变体刺突蛋白的假病毒。

Antibodies Targeting Two Epitopes in SARS-CoV-2 Neutralize Pseudoviruses with the Spike Proteins from Different Variants.

作者信息

Yang Chee-Hing, Li Hui-Chun, Lee Wen-Han, Lo Shih-Yen

机构信息

Department of Laboratory Medicine and Biotechnology, Tzu Chi University, Hualien 97004, Taiwan.

Department of Biochemistry, Tzu Chi University, Hualien 97004, Taiwan.

出版信息

Pathogens. 2021 Jul 9;10(7):869. doi: 10.3390/pathogens10070869.

DOI:10.3390/pathogens10070869
PMID:34358019
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8308897/
Abstract

The COVID-19 pandemic was caused by SARS-CoV-2 infection. To prevent the spread of SARS-CoV-2, an effective vaccine is required. Two linear peptides from potential B-cell epitopes in the spike protein of SARS-CoV-2 (a.a. 440-460; a.a. 494-506) were synthesized and used to immunize rabbits. High-titer antibodies of IgG were produced, purified, and verified by Western blot analysis. Antibodies against these two epitopes could effectively neutralize SARS-CoV-2 pseudoviral particles with the spike proteins from not only the original strain (basal; wild-type), but also a strain with a single point mutation (D614G), and two other emerging variants (the Alpha and Beta variants) prevalent around the world, but not from SARS-CoV. In conclusion, antibodies against these two epitopes are protective. This information is important for the development of vaccines against SARS-CoV-2.

摘要

新冠疫情由严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染所致。为防止SARS-CoV-2传播,需要一种有效的疫苗。合成了来自SARS-CoV-2刺突蛋白中潜在B细胞表位的两种线性肽(氨基酸440 - 460;氨基酸494 - 506),并用于免疫兔子。产生了高滴度的IgG抗体,进行了纯化,并通过蛋白质印迹分析进行了验证。针对这两个表位的抗体不仅可以有效中和具有来自原始毒株(基础型;野生型)刺突蛋白的SARS-CoV-2假病毒颗粒,还可以中和具有单点突变(D614G)的毒株以及全球流行的另外两种新出现的变异株(Alpha和Beta变异株)的SARS-CoV-2假病毒颗粒,但不能中和来自SARS-CoV的假病毒颗粒。总之,针对这两个表位的抗体具有保护作用。该信息对于开发抗SARS-CoV-2疫苗很重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e076/8308897/773c5d2d2b3e/pathogens-10-00869-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e076/8308897/cdb8e87b7aef/pathogens-10-00869-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e076/8308897/caed3278c3a1/pathogens-10-00869-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e076/8308897/5c2183223f6f/pathogens-10-00869-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e076/8308897/773c5d2d2b3e/pathogens-10-00869-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e076/8308897/cdb8e87b7aef/pathogens-10-00869-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e076/8308897/caed3278c3a1/pathogens-10-00869-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e076/8308897/5c2183223f6f/pathogens-10-00869-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e076/8308897/773c5d2d2b3e/pathogens-10-00869-g004.jpg

相似文献

1
Antibodies Targeting Two Epitopes in SARS-CoV-2 Neutralize Pseudoviruses with the Spike Proteins from Different Variants.靶向严重急性呼吸综合征冠状病毒2(SARS-CoV-2)两个表位的抗体可中和携带不同变体刺突蛋白的假病毒。
Pathogens. 2021 Jul 9;10(7):869. doi: 10.3390/pathogens10070869.
2
mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants.mRNA-1273疫苗可诱导产生针对全球新冠病毒变异株刺突突变体的中和抗体。
bioRxiv. 2021 Jan 25:2021.01.25.427948. doi: 10.1101/2021.01.25.427948.
3
Bioinformatics analysis of epitope-based vaccine design against the novel SARS-CoV-2.基于表位的新型 SARS-CoV-2 疫苗设计的生物信息学分析。
Infect Dis Poverty. 2020 Jul 10;9(1):88. doi: 10.1186/s40249-020-00713-3.
4
Variations in SARS-CoV-2 Spike Protein Cell Epitopes and Glycosylation Profiles During Global Transmission Course of COVID-19.SARS-CoV-2 刺突蛋白细胞表位和糖基化特征在 COVID-19 全球传播过程中的变化。
Front Immunol. 2020 Sep 4;11:565278. doi: 10.3389/fimmu.2020.565278. eCollection 2020.
5
Immunodominant Linear B-Cell Epitopes of SARS-CoV-2 Spike, Identified by Sera from K18-hACE2 Mice Infected with the WT or Variant Viruses.通过感染野生型或变异病毒的K18-hACE2小鼠血清鉴定的新冠病毒刺突蛋白的免疫显性线性B细胞表位
Vaccines (Basel). 2022 Feb 7;10(2):251. doi: 10.3390/vaccines10020251.
6
The immunodominant and neutralization linear epitopes for SARS-CoV-2.针对 SARS-CoV-2 的免疫显性和中和线性表位。
Cell Rep. 2021 Jan 26;34(4):108666. doi: 10.1016/j.celrep.2020.108666.
7
The Spike D614G mutation increases SARS-CoV-2 infection of multiple human cell types.刺突 D614G 突变增加了 SARS-CoV-2 对多种人类细胞类型的感染。
Elife. 2021 Feb 11;10:e65365. doi: 10.7554/eLife.65365.
8
Scrutinizing the SARS-CoV-2 protein information for designing an effective vaccine encompassing both the T-cell and B-cell epitopes.深入研究 SARS-CoV-2 蛋白信息,设计一种既包含 T 细胞表位又包含 B 细胞表位的有效疫苗。
Infect Genet Evol. 2021 Jan;87:104648. doi: 10.1016/j.meegid.2020.104648. Epub 2020 Nov 29.
9
Antibody signature induced by SARS-CoV-2 spike protein immunogens in rabbits.兔源 SARS-CoV-2 刺突蛋白免疫原诱导的抗体特征。
Sci Transl Med. 2020 Jul 1;12(550). doi: 10.1126/scitranslmed.abc3539. Epub 2020 Jun 8.
10
Development of a Candidate TMV Epitope Display Vaccine against SARS-CoV-2.一种针对严重急性呼吸综合征冠状病毒2的候选烟草花叶病毒表位展示疫苗的研发。
Vaccines (Basel). 2024 Apr 23;12(5):448. doi: 10.3390/vaccines12050448.

引用本文的文献

1
A rapid simple point-of-care assay for the detection of SARS-CoV-2 neutralizing antibodies.一种用于检测新型冠状病毒 2 型(SARS-CoV-2)中和抗体的快速简便即时检测方法。
Commun Med (Lond). 2021 Nov 11;1:46. doi: 10.1038/s43856-021-00045-9. eCollection 2021.

本文引用的文献

1
Emerging SARS-CoV-2 Variants and Impact in Global Vaccination Programs against SARS-CoV-2/COVID-19.新型严重急性呼吸综合征冠状病毒2(SARS-CoV-2)变体及其对全球严重急性呼吸综合征冠状病毒2/冠状病毒病(COVID-19)疫苗接种计划的影响
Vaccines (Basel). 2021 Mar 11;9(3):243. doi: 10.3390/vaccines9030243.
2
SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)501Y.V2变体的传染性并不更强,但确实存在免疫逃逸。
Cell. 2021 Apr 29;184(9):2362-2371.e9. doi: 10.1016/j.cell.2021.02.042. Epub 2021 Feb 23.
3
Detection of a SARS-CoV-2 variant of concern in South Africa.
南非出现一种令人关注的 SARS-CoV-2 变异株。
Nature. 2021 Apr;592(7854):438-443. doi: 10.1038/s41586-021-03402-9. Epub 2021 Mar 9.
4
Sixteen novel lineages of SARS-CoV-2 in South Africa.南非出现 16 种新型 SARS-CoV-2 谱系。
Nat Med. 2021 Mar;27(3):440-446. doi: 10.1038/s41591-021-01255-3. Epub 2021 Feb 2.
5
Emergence of SARS-CoV-2 B.1.1.7 Lineage - United States, December 29, 2020-January 12, 2021.SARS-CoV-2 B.1.1.7 谱系的出现 - 美国,2020 年 12 月 29 日-2021 年 1 月 12 日。
MMWR Morb Mortal Wkly Rep. 2021 Jan 22;70(3):95-99. doi: 10.15585/mmwr.mm7003e2.
6
The 501.V2 and B.1.1.7 variants of coronavirus disease 2019 (COVID-19): A new time-bomb in the making?2019冠状病毒病(COVID-19)的501.V2和B.1.1.7变体:正在形成的新定时炸弹?
Infect Control Hosp Epidemiol. 2022 Mar;43(3):415-416. doi: 10.1017/ice.2020.1434. Epub 2021 Jan 11.
7
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Codon Usage and Replicative Fitness.严重急性呼吸综合征冠状病毒2(SARS-CoV-2):密码子使用与复制适应性
Glob Med Genet. 2020 Oct;7(3):92-94. doi: 10.1055/s-0040-1721080. Epub 2020 Dec 2.
8
Evaluating the Efficacy of Coronavirus Disease 2019 Vaccines.评估 2019 冠状病毒病疫苗的效力。
Clin Infect Dis. 2021 Oct 20;73(8):1540-1544. doi: 10.1093/cid/ciaa1863.
9
Covid-19: New coronavirus variant is identified in UK.新冠疫情:英国发现新型冠状病毒变种。
BMJ. 2020 Dec 16;371:m4857. doi: 10.1136/bmj.m4857.
10
Design of an epitope-based peptide vaccine against the SARS-CoV-2: a vaccine-informatics approach.基于表位的 SARS-CoV-2 肽疫苗设计:疫苗信息学方法。
Brief Bioinform. 2021 Mar 22;22(2):1309-1323. doi: 10.1093/bib/bbaa340.